Navigation Links
Ringing endorsement: Women prefer contraceptive ring over patch
Date:2/4/2008

PITTSBURGH, Feb. 4 In the first study to directly compare a contraceptive vaginal ring and skin patch, more women indicated overall satisfaction with the vaginal ring, researchers report in the current issue of Obstetrics and Gynecology, a publication of the American College of Obstetricians and Gynecologists. Using the same combination of hormones included in prescription birth control pills, these products became available in 2002 as an alternative to taking a pill every day. Ring and patch are left in place for three weeks at a time.

The study evaluated the experiences of 500 women who were randomly assigned to use the ring or patch for four consecutive menstrual cycles in 2005 and 2006. Of these, 249 used the ring and 251 used the patch. In addition to regular study visits for physical evaluation, participants completed a questionnaire and talked to investigators by phone following the study period.

What we found is that more women are happier with the ring than the patch, said Mitchell Creinin, M.D., professor of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine and the studys first author. On the whole, they report fewer complications, and a significant majority preferred the ring to their pill. The University of Pittsburgh served as sponsoring institution for the trial, which was conducted at 10 centers nationwide.

In November 2005, the U.S. Food and Drug Administration issued a warning regarding estrogen levels in the contraceptive patch and related risk of blood clots, changing the package labeling to reflect the warning. Participants enrolled in the study, regardless of study product assignment, were given standard, written information about the warning. Five women who used the contraceptive patch said they were influenced by the FDA labeling change, opting to discontinue use at the conclusion of the study.

Overall, however, patch users were twice as likely to discontinue using the product by the end of the third cycle, and seven times more likely to say they had no wish to continue once the study was over, said Dr. Creinin, who also is director of family planning at Pitt and a senior investigator at the Pitt-affiliated Magee-Womens Research Institute. The most commonly cited reasons for discontinuation were adverse effects, including longer periods, cramps, nausea, mood swings, skin irritation or problems with the patch falling off. The most common reasons for discontinuation among women who used the ring were discomfort and more frequent vaginal discharge.

Although oral contraceptives are the most commonly used reversible form of contraception in the United States, continuation rates are only 40 percent at six months of use, the authors write. In addition, prior studies have shown that in the third month of use, about half of women miss three or more pills each cycle, likely decreasing contraceptive effectiveness.

The two alternative delivery systems for combined hormonal contraceptives had not been evaluated in a single randomized trial, making it difficult for clinicians to compare and contrast these options for their patients, Dr. Creinin said. But now we can provide more accurate counseling to patients who might be interested in a nondaily birth control method.


'/>"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Overactive nerves in head and neck may account for ringing in the ears
2. Pittsburgh Ringing in New Year with Environmentally Friendly Ball
3. Long Term Care Leader Applauds Clinton for Bringing Critical Issue of Senior Care into the Presidential Debate
4. NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud
5. Packard Childrens Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home
6. CycleBeads help women manage their fertility
7. Study Finds Women Pay More Attention to Their Hair Than Their Hearts
8. PA Commission for Women Announces Shocking Pink Osteoporosis Campaign in Rural PA
9. Gene linked to preterm birth among Hispanic women
10. Stars Don Red to Raise Awareness of Womens Heart Risk
11. Women Believe Economy Is Top Issue in 2008 Election
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation pioneer ... East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at the Hynes ... 40 speakers — representing such thought-leading companies as JP Morgan Chase, GE ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy ... industry-leading compliance software, The Guard®, has helped another long-time client pass their Department ... and properly satisfy the law. , Thanks to the help of the Compliancy ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... campaign, “Humans With Vaginas.” The goal is to ignite conversation via social media ... care products. The brand has declared September “Humans with Vaginas” month, releasing a ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... millions of older Americans at risk of price gouging for their prescription drugs, ... League (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency ...
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take on one ... better one’s life through God. “The Trials I Face to Receive God’s Grace” is ... found a love for writing. Green feels that expressing his feelings through prayer will ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
Breaking Medicine Technology: